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Abstract 
Milk fat globule membrane (MFGM) protein is known to have several health benefits, 
including an anti-sarcopenia effect; however, its mechanism is unclear. The aim of 
this study was to investigate the potential mechanism of action of the MFGM protein. 
The MFGM protein was extracted and separated into 4 fractions, and Fraction 2 
(57 % of total MFGM) demonstrated the greatest effect on C2C12 cell proliferation. 
Milk fat globule-EGF factor 8 (MFG-E8) accounted for 82.35 % of the MFGM 
protein. The effects of whole Fraction 2 (100 μg/mL, 200 μg/mL and 300 μg/mL) on 
cell proliferation and morphology were measured. Using qRT-PCR or a Western blot 
assay, several regulatory factors, e.g., PI3K P85α, p-pI3K p85α (Tyr 508), Akt, p-Akt 
(Ser 473), mTOR and p-mTOR (Ser 2448), were measured in cells incubated with 200 
μg/mL of Fraction 2 with or without wortmannin. The results demonstrated that 
Fraction 2 induced C2C12 cell proliferation in a dose-dependent manner, upregulated 
the mRNA expression of mTOR and p70S6K, and activated PI3K, Akt, mTOR and 
P70S6K phosphorylation; however, Fraction 2 inhibited FOXO3a and 4E-BP. The 
results demonstrate that the MFGM protein, predominantly MFG-E8, promotes cell 
proliferation through the PI3K/Akt/mTOR signaling pathway. This study elucidated 
the molecular mechanism of the MFGM protein, primarily MFG-E8, in promoting 
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C2C12 cell proliferation via the PI3K/Akt/mTOR/P70S6K signal pathway. 
Keywords：Milk fat globule membrane; MFG E8; PI3K/Akt/mTOR pathway; C2C12 
cell; Western blot; sarcopenia. 
1. Introduction 
Sarcopenia is a disease that is associated with the ageing process in humans. It is 
associated with a decline in skeletal muscle mass and strength as well as an increase 
in muscle fatigability [1]. After 30 years of age, lean muscle mass loss takes place at 
the rate of approximately 1 % every year [2]. Age-related sarcopenia relates to 
metabolism (anabolism and catabolism of muscle protein). Compared to a younger 
person, the elderly (aged > 60) produce less muscle protein from the same amount of 
dietary protein [3], have a slower rate of basal, post-absorptive myofibrillar muscle 
protein synthesis and have a more negative net protein balance [4]. Medication, 
hormones, nutrition and resistance training can help treat and prevent sarcopenia. 
Medication is a significant therapeutic tool; however it has side effects. Recently, 
research on nutrition regulation of sarcopenia has received broad attention [5, 6]. 
C2C12 mouse skeletal muscle cells have been widely used as a sarcopenia model 
to study myoblast differentiation, neuromuscular junction formation and muscle 
pharmacology [7]. Increased muscle cell apoptosis of C2C12, in addition to the decline 
in regenerative potential, contributes to age-associated sarcopenia [8]. Thus, a 
combined approach targeting both increased regenerative potential and proliferation 
activity may present a framework for therapeutic intervention of sarcopenia. 
 Milk fat globule membrane (MFGM) is a mixture of primarily lipids and 
membrane specific proteins [9]. MFGM has attracted much attention in protection 
against sarcopenia. Haramizu et al. [10] investigated the effects of habitual exercise 
plus consumption of MFGM and green tea on aging-related deficits in muscle mass 
and function in senescence-accelerated P1 mice. The results indicated that exercise 
plus dietary MFGM can improve muscle function through neuromuscular 
development. Haramizu et al. [11] evaluated the effects of MFGM consumption on 
endurance capacity and energy metabolism in BALB/c mice over a 12-week period. 
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Long-term MFGM intake combined with regular exercise improved endurance 
capacity, as evidenced by swimming time until fatigue, in a dose-dependent manner.  
Phosphatidylinositol 3-kinases (PI3K) are a group of enzymes involved in 
cellular functions, such as cell growth, proliferation, differentiation, motility, survival 
and intracellular trafficking [12] The PI3K/Akt signaling pathway has been implicated 
in the regulation of several important cellular processes, including apoptosis survival, 
proliferation, and metabolism, in skeletal muscle and is activated in response to 
growth factors, such as insulin-like growth factor-I (IGF-I) [13]. Activation of the 
PI3K/Akt pathway is sufficient to induce hypertrophy and block skeletal muscle 
atrophy [14]. Jing et al. [15] reported that PI3K can activate mTOR and downstream 
target proteins (S6K1, S6, 4E-BP1) as well as increase translation initiation and 
protein synthesis in skeletal muscles. Xie et al. [16] observed that the PI3K/Akt 
signaling pathway regulates mTOR/p70S6K activation in C2C12 myoblasts. Activation 
of PI3K as well as its primary downstream effector, Akt, is necessary for proliferation 
and differentiation to occur, and PI3K inhibitors, such as wortmannin and LY294002, 
are able to block myogenesis [17, 18]. Thomas et al. [19] determined the role of 
LY294002 in the PI3K/Akt signaling pathway in C2C12 myotubes and analyzed the 
related impact on cell death parameters occurring within this context. Their results 
indicated that simulated ischemia attenuated PI3K activity is associated with 
decreased Akt-dependent phosphorylation at the level of mTOR and other target 
proteins. MFGM has been demonstrated to be an effector in skeletal muscles [10, 11]; 
however, the molecular mechanism by which the signaling pathway integrates the 
MFGM protein into skeletal muscle cells has not been previously examined, and 
whether the MFGM protein activates the PI3K/Akt/mTOR pathway in C2C12 cell 
proliferation and modulates skeletal muscle protein turnover remains unclear.  
Therefore, the primary purpose of the study is to identify the effects of MFGM 
protein on C2C12 cell proliferation and its signaling pathway. Here, we focused on the 
pathway involved in MFGM protein modulation of the PI3K/Akt/mTOR signaling 
pathway. 
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2 METHODS 
    DEAE Cellulose DE-52 was purchased from Whatman (Maid- stone, Kent, UK). 
The Hoechst 33342/PI kit (Solarbio, China) and radio immunoprecipitation assay 
lysis buffer were purchased from Keygen (Solarbio, China). The BCA protein assay 
kit was purchased from Thermo Fisher (Pittsburgh, PA). Antibodies were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and Abcam (Abcam, 
Cambridge, Mass., USA). All other chemicals and reagents were purchased from 
Sigma (Saint-Louis, MO, USA). 
2.1 Separation and identification of the MFGM protein 
MFGM was prepared as described in our previous study [20, 21] with a slight 
modification. MFGM (0.2 g) was dissolved in PBS buffer (10 ml, pH 8.0), and the 
supernatant was applied to a DEAE Cellulose DE-52 (2.6×60 cm), followed by a 
linear gradient elution of NaCl (0.2 M, 0.5 M and 0.8 M) in the same buffer. Four 
protein fractions (the elution flow rate was 1 mL/min) were collected and detected at 
280 nm by HD-93-1 (Purkinje General Instrument Co. Ltd., Beijing, China). Four 
fractions were collected after dialysis, concentration and freeze-drying, and their 
effects on C2C12 cell proliferation were tested. Among the 4 fractions, Fraction 
2–MFGM P2–was the largest (57 % of all recovered) and also had the strongest effect 
on improving cell proliferation (6 times higher than fraction 3; Fractions 1 and 4 both 
inhibited cell proliferation). Thus, the current study focused on MFGM P2. 
MFGM P2 was then separated by 1-D gel electrophoresis and the highest density 
band at 45 kDa was excised. Total MFGM P2 was subjected to the LC-MS/MS 
assay for further identification of the protein composition based on the method of 
Churchwell et al. [22]. 
2.2. Cell Culture and MTT cell activity assay 
C2C12 murine skeletal muscle myoblasts were supplied by the Chinese Academy 
of Agricultural Sciences (Beijing, China). C2C12 cells were grown in Dulbecco’s 
Modified Eagle medium (DMEM, GIBCO) supplemented with 10 % (v/v) fetal 
bovine serum (FBS, GIBCO), 100 U/ml penicillin, and 100 μg/mL streptomycin 
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(Invitrogen) in a humidified incubator containing 5 % CO2 at 37°C. 
2.3 MTT cell activity assay 
    The effect of the MFGM protein on cell proliferation was first measured using 
the MTT assay [23]. C2C12 cells were inoculated at a density of 5×10
4
/ml on 96-well 
plates and cultured overnight at 37°C. C2C12 cells were then cultured in the same 
medium with MFGM protein P2 (100 μg/mL, 200 μg/mL and 300 μg/mL) and 
MFGM (200 μg/mL) (n = 5) for 24 h, 48 h, and 72 h. Next, 20 μl of MTT (5 mg/ml, 
Sigma) working solution was added to each well and incubated for 4 h at 37°C. After 
the MTT solution was removed, the formazan that formed inside the cells was 
dissolved using DMSO. Absorbance was measured at 490 nm using a microplate 
reader (Model 550, Bio-Rad USA). The cell proliferation rate was calculated using 
the following equation: (OD490 experiment group - OD490 control group)/OD490 
control group. In each group, n = 5. 
2.4 Cells cultured with wortmannin and with or without MFGM P2 
    Wortmannin reagent (Invitrogen, Carlsbad, CA) was introduced to block the 
PI3K signaling pathway of C2C12 cells. C2C12 cells were inoculated at a density of 
5×10
4
/ml in 96-well plates and cultured overnight. C2C12 cells were treated with 
wortmannin at final concentrations of 50 nM/L, 100 nM/L, 200 nM/L, 500 nM/L and 
1000 nM/L for 24 h, 48 h, and 72 h. Control group cells were not given wortmannin 
treatment. Next, C2C12 cell activities were determined by the MTT assay (See section 
2.2).  
    In another experiment, C2C12 cells were inoculated at a density of 5×10
4
/mL in 
96-well plates and cultured overnight at 37°C. C2C12 cells were then cultured in a 
medium containing wortmannin (200 nM/L) with 200 μg/mL of either MFGM or 
MFGM P2 for 24 h, 48 h, and 72 h. Next, the C2C12 cell activity was determined by 
the MTT assay, as described in section 2.2. 
2.5 Confocal scanning laser microscopy (CLSM) measurements 
The C2C12 cell morphology was measured using the Hoechst 33342/PI kit 
(Solarbio, China). The method used was as described by Chen et al. [24] with a slight 
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modification. C2C12 cells were inoculated at a density of 1×10
5
/mL in 6-well plates 
and cultured for 12 h at 37°C. Next, C2C12 cells were treated with 200 nM/L 
wortmannin for 48 h, followed by addition of 200 μg/mL of the MFGM or MFGM P2 
protein to each well and incubation for 48 h. C2C12 cells were then washed with PBS 
and incubated with 1 mL of cell staining buffer, 5 μL of Hoechst 33342 (excitation 
360 nm/emission 465 nm) buffer and 5 μL of PI staining (excitation 488 nm/emission 
620 nm) buffer for 30 min at 4 °C in the dark. The percentage of survival and 
apoptotic cells were then analyzed using CLSM (Leica, Germany). 
2.6 Quantitative real-time PCR 
Total RNA was isolated from C2C12 cells treated with 200 μg/mL of the MFGM 
or MFGM P2 protein for 48 h using the RNAprep Pure Cell/Bacteria Kit (TIANGEN, 
China). For qRT-PCR analysis, cDNA was synthesized by using 3 μg of RNA with the 
PrimeScript
TM 
II 1
st
 strand cDNA synthesis kit (TaKaRa, China) following the 
manufacturer’s protocol. Quantitative real-time qRT-PCR was carried out on an ABI 
7300 Real-Time PCR system (Applied Biosystems) with SYBR Premix Ex Taq
TM
 II 
(TaKaRa). Relative expression was first quantified using the standard curve method, 
and the data were normalized to GAPDH mRNA. The primers used in the study are 
shown in Table 1 [25].  
2.7 Western blot analysis 
C2C12 cells were treated with 200 μg/mL of either MFGM or MFGM P2 for 48 h, 
washed twice with PBS buffer and homogenized in lysis buffer. Total protein was 
extracted and harvested by scraping with a modified radioimmunoprecipitation assay 
buffer containing 100 nM phenylmethylsulfonyl fluoride for 30 min [26]. Following 
centrifugation at 10000 rpm for 15 min at 4℃, the supernatant was sonicated. The 
protein concentration was quantified using a BCA kit (Solarbio, China). Proteins (100 
μg) were loaded onto a 1-D SDS gel (10 % polyacrylamide). Next, proteins were 
transferred onto a nitrocellulose filter membrane (PPLYGEN, China) using a wet 
electrotransfer system (Bio-Rad, USA）for 4 h at 200 mA. The membranes were 
blocked with 5 % non-fat dry milk in Tris-buffered saline with Tween-20 (TBST) 
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buffer for 1 h at room temperature, followed by incubation with primary antibodies 
(Santa Cruz，USA) for each protein, for 1 h at 37 ℃, or overnight at 4 ℃, according 
to the requirements. The concentrations of antibodies were as follows: GAPDH 
(1:500), PI3K (1:500), p-PI3K (1:300), Akt1/2/3 (1:500), p-Akt (Ser 473) (1:800), 
mTOR (1:300), p-mTOR (1:500), P70S6K (1:800) and p-P70S6K (1:800). The 
membrane was washed for 5 minutes three times with TBST, followed by incubation 
with anti-mouse or anti-rabbit secondary antibody (1:2000; Santa Cruz Biotechnology, 
Inc.) at 37 ℃ for 1 h. The membrane was washed with TBST twice and with TBS 
once, 5 min each, and then incubated with alkaline phosphatase until an appropriate 
signal level was obtained. Protein bands were detected by FluorChem Imaging 
Systems (Alpha Innotech, Corp., San Leandro, CA, USA). 
2.8 Statistical analysis 
   All experiments, except when otherwise described, were tested and analyzed in 
triplicate. Analysis of variance (ANOVA) was used to determine significant 
differences (P < 0.05) between means. Statistical analysis was performed using a 
General Linear Model procedure with the SAS 9.1.3 software from SAS Institute, Inc., 
Cary, NC, USA. 
3 Results 
The MFGM protein was extracted by an electric cream separator, and four 
fractions of the MFGM protein were collected by linear gradient elution; the effect of 
each fraction on cell proliferation was initially assessed. Among the four fractions, the 
second fraction, MFGM P2, demonstrated the strongest effect–6-fold higher than 
fraction 3–and both fractions 1 and 4 inhibited cell proliferation. The composition of 
MFGM protein 2 was then analyzed; the effect of MFGM P2 on C2C12 cell 
proliferation and its potential for participating in the PI3K/Akt signaling pathway 
were further investigated. (The work flow is shown in Fig. 1.) 
3.1 The composition of MFGM protein Fraction 2, MFGM P2   
The components of MFGM P2 were confirmed by SDS-PAGE (Fig. 2A) and 
LC-MS/MS. The similarity search was based on sequence alignment in Uniprot. The 
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results demonstrated that there were 62 proteins identified in MFGM P2. The major 
components of MFGM P2 was lactadherin (MFG-E8), accession NO: tr|Q3T0K7|. 
Among them, MFG-E8 accounted for 82.35 % of MFGM P2. 
3.2 Effect of MFGM and MFGM P2 on cell viability  
    C2C12 cells were treated with 100 μg/mL, 200 μg/mL or 300 μg/mL MFGM P2 
in 96-well plates for 24 h, 48 h and 72 h, and cell proliferation was measured by the 
MTT assay (Fig. 2B). The results demonstrated that the cell proliferation activity 
increased with time as well as with concentration, but decreased at 72 h. The 
proliferation rate reached a maximum (35.8 %) at 200 μg/mL at 48 h. The order of the 
proliferation rate with different concentrations of MFGM P2 was as follows: 200 
μg/mL >100 μg/mL > 200 μg/mL > control > 300 μg/mL. Thus, the concentration of 
200 μg/mL of MFGM P2 and incubation time of 48 h were applied for further 
experimentation.  
3.3 Effect of MFGM P2 on the expression of related genes of the PI3K/AKT 
pathway 
The mRNA levels of mTOR, FOXO3a, 4E-BP1 and P70S6K were determined 
by quantitative real-time PCR experiments (Fig. 3). Compared to the control group, 
the mTOR and P70S6K mRNA levels in the MFGM group were increased by 10 % 
and 157 %, respectively; the FOXO3a and 4E-BP1 mRNA levels were reduced by 
12 % and 31 %, respectively. Compared to the MFGM group, the mTOR and P70S6K 
levels in the MFGM P2 group were significantly increased by 109 % and 149 %, 
respectively, while the FOXO3a and 4E-BP1 mRNA levels were reduced by 5 % and 
31 %, respectively. 
3.4 Effect of MFGM P2 on signaling molecules involved in protein synthesis and 
energy regulation of the PI3K /Akt activity 
To determine the effects of MFGM P2 on signaling molecules involved in 
protein synthesis and energy regulation, cells were treated with 200 μg/mL MFGM or 
MFGM P2 and incubated for 48 h, followed by Western blot analysis. As shown in 
Fig. 4, PI3K P85α, p-pI3K p85α (Tyr 508), Akt, p-Akt (Ser 473), mTOR and p-mTOR 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
9 
 
(Ser 2448) were all observed to be constitutively expressed during C2C12 cell 
proliferation. Compared to the MFGM group or control group, the endogenous levels 
of both PI3K p85 and p-pI3K p85α (Tyr508) subunits were increased. Among them, 
total mTOR expression was not altered significantly, but the p-mTOR levels were 
significantly increased compared to both the control and MFGM groups. These results 
demonstrate that both MFGM and MFGM P2 not only increase the total PI3K, AKT 
mTOR and p70S6K protein levels but also increase the phosphorylated PI3K, AKT, 
mTOR and p70S6K protein levels. Therefore, both MFGM and, especially, MFGM 
P2 significantly increased C2C12 cell proliferation via activation of the PI3K/Akt 
pathway.  
3.5 Effect of MFGM or MFGM P2 with wortmannin on cell viability  
    To further investigate the role of PI3K/AKT signaling on the effect of MFGM P2 
on C2C12 cell proliferation, wortmannin–an inhibitor of PI3K–was used to enhance the 
sensitization of C2C12 cells to investigate whether C2C12 cell proliferation, which his 
improved by MFGM P2, predominantly MFG-E8, activated the PI3K signaling 
pathway. 
3.5.1 Effect of wortmannin on the growth of C2C12 cells 
To determine whether inhibition of PI3K activity by wortmannin affects cell 
growth, C2C12 cells were treated as described above, and cell growth was analyzed by 
the MTT assay. The effects of wortmannin on the growth of C2C12 cells are shown in 
Fig. 5. Cell growth was inhibited with each wortmannin treatment (50 nM/L, 100 
nM/L, 200 nM/L, 500 nM/L or 1000 nM/L for 24 h, 48 h and 72 h) in a time- and 
concentration-dependent manner. An inhibition rate of 43.8 % was achieved at a 
concentration of 1000 nM/mL during 48 h. The order of inhibition rate of wortmannin, 
from high to low, was as follows: 1000 nM/L > 500 nM/L > 200 nM/L > 100 nM/L > 
50 nM/L. However, considering the cell growth activity and dose-inhibition rate of 
the drug, the concentration of 200 nM/L wortmannin and 48 h incubation time were 
applied for further experiments. 
3.5.2 Effect of MFGM P2 on the proliferation of C2C12 cells 
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To investigate the effect of the MFGM protein on the PI3K signaling pathway, 
the effects of wortmannin with 200 μg/mL of MFGM or MFGM P2 on the growth of 
C2C12 cells for 24 h, 48 h and 72 h were examined. The results (Fig. 5 B) 
demonstrated that cell proliferation activity increased with time as well as with 
concentration, but decreased at 72 h. The proliferation rate reached a maximum 
(22.8 %) with 200 μg/mL for 48 h. The order of proliferation rate was as follows: 
MFGM P2 > MFGM > control. Thus, wortmannin with MFGM P2 and an incubation 
time of 48 h were applied for further experiments. 
3.5.3 Effect of wortmannin and MFGM P2 on C2C12 cell viability 
The results of CLSM demonstrated that the cell number in the normal group was 
higher than that in the wortmannin group, and the highest cell numbers were seen in 
the MFGM P2 group. The order of the magnitude of cell numbers from high to low 
was as follows: MFGM P2 group (55.6 %) > MFGM (22.2 %) > Control, which was 
calculated by (cell number in assessed group-control group)/control group (Fig. 6). 
3.6 Activation of the PI3K/AKT signaling pathway by MFGM P2 
PI3K activation is typically indispensable for cell proliferation, PI3K plays a 
central role in cell signaling and leads to cell proliferation, survival, motility, secretion, 
and specialized cell responses, such as the respiratory burst of granulocytes [27]. To 
confirm whether the MFGM protein affects the PI3K/AKT signaling pathway in 
C2C12 cells, the PI3K protein and phosphorylation levels were detected using Western 
blot analyses. Compared to the control and MFGM groups, MFGM P2 promoted the 
phosphorylation of PI3K in C2C12 cells (Fig. 7 A).  
3.6.1 Effect of MFGE8 and wortmannin on Akt and phospho-Akt serine 473 
PI3K and Serine 473-phosphorylation of Akt was increased significantly (p<0.03) 
in cells cultured with MFGM P2 compared to both the control and MFGM groups. 
The extent of alterations in the AKT levels observed after MFGM P2 treatment 
reflected the previous findings for PI3K and serine 473 (Fig. 7B). Compared to the 
group with only MFGM P2, approximately 23.3 % of phosphorylation of Akt at the 
serine 473 position was decreased in cells cultured with both wortmannin and MFGM 
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P2. Analogous results were seen in other reports where wortmannin or another 
inhibitor (LY294002) was added to the medium [19, 27, 28]. 
3.6.2 Effect of MFGM P2 and wortmannin on mTOR and p-mTOR Ser2448 
Akt phosphorylates mTOR directly at the serine 2448 motif [29]. Compared to 
the control and MFGM groups, a significantly higher Akt-dependent phosphorylation 
of mTOR was observed after treatment with MFGM P2 at 48 h. Inhibition of the PI3K 
pathway with wortmannin during acute MFGM P2 treatment also led to statistically 
significant increase in Akt dependent mTOR phosphorylation (Fig. 7C).   
3.6.3 Increased phosphorylation of P70S6K in response to Akt knockdown 
Akt is the principal molecule involved in PI3K-mediated mTOR activation, 
which is an important parameter that was used to identify the levels of phosphorylated 
P70S6K. In this study, to determine whether activation of P70S6K resulted from 
PI3K-induced activation of mTOR, wortmannin was introduced. The results 
demonstrated that P70S6K phosphorylation and activation were prevented by 
wortmannin. Compared to the control and MFGM groups, phosphorylation of 
P70S6K was significantly higher after treatment with MFGM P2 at 48 h（Fig. 7D). 
In sum, these results indicate that MFGM P2 promotes expression of the 
PI3K/Akt/mTOR signaling pathway-related total proteins as well as phosphorylated 
proteins, and the ratio of phosphorylated protein to total protein was increased. 
Discussion 
    The C2C12 murine myogenic cell line is a popular model for studying 
myogenesis in vitro [30]. Previous studies [10, 11] demonstrated that MFGM 
improves cell proliferation. As MFGM contains a variety of components, it is 
important to investigate which individual component is responsible for the 
improvement of cell proliferation and what mechanisms underlie this role.  
    To achieve these objectives, first, cellulose DEAE-52 was used to purify MFGM 
proteins, which were further separated into 4 fractions; the effect of each individual 
fractions on C2C12 cell proliferation was tested. Among the four fractions, fraction 2, 
MFGM P2, showed the best performance. The composition of this protein was further 
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identified by LC-MS/MS. Among the 62 proteins identified in fraction 2, MFG-E8 
composed 82.35 % of the total protein. MFG-E8 is also known as lactadherin, a 
protein encoded by the MFG-E8 gene in humans. MFG-E8 is a major glycoprotein of 
the milk fat globule, a protein and triglyceride-rich membrane-bound vesicle secreted 
from the mammary epithelium during milk production [31]. Previous studies have 
demonstrated that MFGM P2 can promote C2C12 cell proliferation based on the results 
of flow cytometry, laser confocal microscopy and transmission electron microscopy 
analyses [32]. In this study, the anti-sarcopenia effect of MFGM P2 was analyzed. 
Because MFG-E8 comprised 82.35 % of the total protein in MFGM P2, the effect of 
MFGM P2 was considered to be a potential effect of MFG-E8, even though further 
research is required for verification of this hypothesis. 
The results from the MTT assay suggested that all three concentrations of 
MFGM P2 improve cell proliferation, but the highest proliferation rate was in cells 
cultured with 200 μg/mL. This dosage is a good reference for future clinical trials. 
The results from confocal scanning laser microscopy demonstrated that the C2C12 cell 
density was higher in the MFGM P2 group than in the MFGM group. Therefore, 
MFGM P2, predominantly MFG-E8, was more beneficial for improving cell 
proliferation. 
The PI3K/Akt signaling pathway plays a central role in diverse cellular function, 
including proliferation, apoptosis, cell survival and metabolism [33, 34]. 
Overexpression of Akt has been observed to promote cell proliferation and prevent 
apoptosis in several cell types, resulting in a resistance to or delay of cell death. Few 
studies have demonstrated the effect of MFG-E8 on the PI3K/Akt signaling pathway 
[35, 36]. Neutzneri et al.[36] have reported that MFG-E8 regulates colorectal cancer 
cell migration, invasion and epithelial-to-mesenchymal transition through activation 
of the PI3K/Akt signaling pathway, which inhibits cell growth and promotes cell 
apoptosis. As shown in Fig. 3, the results indicate that MFG-E8 may regulate C2C12 
cell proliferation through activation of the PI3K/Akt signaling pathway via an 
increase in mTOR and P70S6K protein expression and inhibition of FOXO3a and 
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4E-BP1 protein expression (Fig. 3). Furthermore, the effect of MFG-E8 on the 
PI3K/Akt signaling pathway-related total protein and phosphorylation protein was 
investigated by western blot analysis. 
Akt promotes cell proliferation through phosphorylation of several downstream 
effectors and the regulation of various transcription factors [19]. The results 
demonstrated that expression of the target genes FOXO3a and 4E-BP was inhibited by 
inhibition of their transcriptional activity, whereas the transcriptional activities of 
mTOR and P70S6K were enhanced. However, compared to the inhibition of the 
transcriptional activity of FOXO3a and 4E-BP, the promotion of transcriptional 
activity of mTOR and P70S6K was significant. Thus, the elevated PI3K/Akt activity 
in C2C12 cell proliferation may be due to an increase in MFG-E8. Which in turn is 
tightly regulated by mTOR, a key controller of protein synthesis in the cell.  
The above conclusion was confirmed by the results of the western blot assay (Fig. 
4), which demonstrated that MFGM P2 regulated transcription and expression of the 
PI3K P85α, p-pI3K p85α (Tyr 508), Akt, p-Akt (Ser 473), mTOR and p-mTOR (Ser 
2448) to affect cell growth. Previous studies demonstrated that the role of MFG-E8 in 
cell growth, invasion, and metastasis promoted resistance to apoptosis, 
epithelial-to-mesenchymal transition, and angiogenesis through activation of the 
PI3K/Akt signaling pathway [35, 37]. However, there have been no reports regarding 
the effect of MFG-E8 on C2C12 cell growth. Promotion of cell proliferation by 
MFGM P2 might be related to the effect of MFG-E8 on the PI3K/Akt/mTOR 
signaling pathway. The western blotting results for several proteins linked to the 
PI3K/Akt/mTOR signaling pathway demonstrated that MFGM P2 plays a vital role in 
cell proliferation via the PI3K pathway (Fig. 5). To further confirm that MFG-E8 
promotes C2C12 cell proliferation via the PI3K/Akt signaling pathway, the effect of 
MFG-E8 on PI3K/Akt signaling pathway-related total protein and phosphorylated 
protein expression was examined. Wortmannin, a selective inhibitor of the PI3K 
pathway, was introduced. The results demonstrated that there was a gradual decrease 
in the MTT reductive capacity when C2C12 cells were incubated with increasing 
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concentrations of wortmannin for 24 h, 48 h and 72 h (Fig. 2 B). There was a 
significant decrease in MTT reductive capacity, which was only achieved when using 
a high concentration of wortmannin combined with MFGM P2. The promotion of 
skeletal myoblast cell proliferation by MFG-E8 was inhibited by the PI3K inhibitor 
wortmannin. 
    Akt (also named protein kinase B) is a serine/threonine kinase, operates 
downstream of PI3K, and has a key responsibility in regulating signaling pathways 
concerning cell survival [19, 38]. Akt activation prevents muscle atrophy including 
sarcopenia [39]. Phosphorylation of Akt at both its serine 473 and threonine 308 
motifs is necessary for its complete activation [40]. Inhibition of Akt activation with 
wortmannin, also blocks activation of PI3K, depressing the expression of p-Akt 
Ser473 [41]. In this study, compared to the normal group, PI3K, Akt，mTOR, and 
P70S6K phosphorylation were reduced when C2C12 cells were cultured with both 
MGFM P2 and wortmannin, which further indicated that MFG-E8 targets Akt 
phosphorylation, which is regulated upstream by PI3K in the model. Wortmannin can 
not only bind to class I PI3K as well as other PI3K-related kinases but can also bind 
to other novel targets that are seemingly unrelated to the PI3K family [19, 42]. It is 
noteworthy that the decrease in p-Akt was comparatively small given the large 
decrease in the PI3K activity [19, 43].  
 mTOR is a key enzyme in the PI3K/AKT signaling pathway, the activity of 
which is firmly regulated by cellular nutrient availability. Depletion of amino acids 
diminishes mTOR-dependent IGF-II expression in C2C12 myogenesis [44]. MFG-E8 
increased intracellular mTOR phosphorylation. mTOR is negatively regulated by a 
heterodimer made up of the TSC (tuberous sclerosis complex) proteins: TSC1 and 
TSC2. TSC2 has been defined as a target for Akt phosphorylation in vivo/vitro [19, 
45]. Indeed, a decrease in Akt-dependent stimulation of phospho-TSC2 and 
phospho-mTOR was observed during MFG-E8. Supplementation with a PI3K 
inhibitor confirmed the role for PI3K control at these motifs. Jozwiak et al.[45] 
reported that mTOR regulates synthesis of both proteins, via phosphorylation and 
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activation of p70S6 kinase (p70S6K), as well as by phosphorylation and release of the 
inhibitory effect of initiation factor 4E-BP1 and protein degradation via transcription 
factors of the Foxo family. Phosphorylation of both p70S6K and 4E-BP1 leads to the 
activation of a pathway that promotes protein synthesis and translation initiation. 
Therefore, supplementation with a PI3K inhibitor confirmed the role for PI3K control 
at these motifs. 
In summary, the MFGM protein promotes C2C12 cell proliferation through 
activation of the PI3K/Akt/mTOR signaling pathway (Fig. 8), promotes synthesis of 
the regulatory and catalytic subunit of PI3K, and causes PI3K p85 subunit translation 
as well as an increase in its relative capacity for catalyzed production of PIP3 
(phosphatidylinositol (3,4,5)-trisphosphate). PDK1(3-phosphoinositide dependent 
protein kinase-1) binding to the cell membrane by plekstrin homology domain 
activates PI3K. Phosphorylation of Akt ser473 was increased by PDK2, and Akt was 
activated. The downstream target TSC2 was phosphorylated by the GTP protein 
kinase and its activity was inhibited, resulting in activation of mTOR [46]. These 
results were obtained in a C2C12 cell model; however, one cell line may not be enough 
to certify the mechanism of the MFGM protein on C2C12 cell proliferation. 
Furthermore, the effects of MFG-E8 on skeletal muscle growth and expression of the 
PI3K/Akt pathway-related proteins will be validated in rats via in vivo experiments. 
In addition to the pathway that we explored, several other unknown factors might be 
involved in cell proliferation. 
Conclusion 
This study provides a novel insight into the positive effect of the MFGM protein, 
especially MFG-E8, on the improvement of sarcopenia and its potential mechanisms 
underlying the PI3K/Akt signaling pathway in C2C12 cells, a model of sarcopenia. 
Experiments using an animal model are being conducted for further confirmation. 
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Table 
 
Table 1. Primer sequences 
Primer Forward primer Reverse primer 
GAPDH ACCACAGTCCATGCCATCAC TCCACCACCCTGTTGCTGTA 
p70s6k GGGAAGGCTTTGCAGTTTAC TCCAGTCCCTCACGAACAAA 
4E-BP1 CCAGCAGCCCGGAAGATAA GGTCCCTTAAATGTCCATCTCA 
mTOR CTGGGACTCAAATGTGTGCAGTTC GAACAATAGGGTGAATGATCCGGG 
FOXO3a TCGCGCACCAATTCCAAC TCGCTGTGGCTGAGTGAGTC 
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Figure 
 
Figure. 1 The flow chart of this study 
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Figure. 2 SDS-PAGE analysis of the MFGM P2 (A), and the effect of MFGM P2 on C2C12 
growth(B). 
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Figure. 3 The effect of  MFGM P2 on mRNA levels of mTOR, FOXO3a, 4E-BP1 and P70S6K 
at 48 h; The relative mRNA levels were calculated using the △△Ct methods, △△Ct=target group 
(CT of target genes -CT of CAPDH )-control group (CT of target genes -CT of GAPDH), and data 
were expressed as a fold change (n=4). The results are expressed as mean ± SEM, *p<0.05, 
**p<0.01 vs. Control and MFGM (n=3). 
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Figure. 4 The effect of MFGM or MFGM P2 on PI3K, p-PI3K, Akt, p-Akt Ser 473, 
p-mTOR Ser 2448, p70s6k and p-p70s6k expression at 48h. The results are expressed as mean ± 
SEM, *p<0.05, **p<0.01 vs. Control or MFGM (n=3). 
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Figrue. 5 The effect of WM or MFGM P2 on cell viability. A) The effect of WM on C2C12 cell 
growth, the cell inhibition rate was calculated as in the following equation: (OD490 experiment 
group - OD490 control group)/OD490 control group. In each group, n = 5.*p<0.05, **p<0.01 vs. 
Control; B) The effect of wortmannin (200 nM/L) and MFGM P2 (200 µg/mL) on cell growth,* 
p<0.05, **p<0.01 vs. Control or MFGM (n=4). 
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Figure. 6 The effect of MFGM P2 on cell morphology by CLSM analysis. Wortannin can inhibit 
cell grow, even increase apoptosis (arrows), which can be blocked by MFGM P2. 
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Figure. 7 The effect of individual or combined with MFGM, MFGM P2 and wortmannin on the 
expression of total and phosphorylated PI3K p85α (Tyr 508) (A); Akt. (Ser473) (B); mTOR (C), 
p70S6K (D). Data are presented as mean ± S.E.M, **p<0.01, *p<0.05 (n=3). 
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Figure. 8 The role of MFG-E8 in C2C12 cell proliferation via PI3K/Akt signal pathway. Based on 
the results, we proposed that the mechanism of MFG-E8 on C2C12 cell proliferation might be 
described as follows: MFG-E8 promotes the regulatory and catalytic subunit of PI3K synthesis, 
PI3K p85 subunit translation was induced and further increased relative capacity for catalyzed 
production of PIP3. Then PDK1 binding to the cell membrane by the plekstrin homology domain, 
and with subsequent PI3K activation, then phosphorylation of Akt ser473 was increased by PDK2, 
and Akt was activation completely. The downstream targets TSC2 was phosphorylated and the 
GTP protein kinase activity was inhibed, mTOR compound was activated, mTOR regulation both 
protein synthesis, via phosphorylating and activating p70S6K, as well as phosphorylating and 
releasing the inhibitory effect of initiation factor 4E-BP1 and protein degradation. The diagram of 
the mechanism of MFG-E8 on cell proliferation was modified from Jeong, Gao and Huang et al 
[47-49]. 
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Highlights 
•The main protein in MFGM protein fraction 2 was milk fat globule-EGF factor 8 
(MFG-E8), it was identified and quantified by LC-MS/MS.  
•The effect of MFG-E8 on C2C12 cell growth was analysed by MTT assay, CSLM, 
qRT-PCR and Western blot. 
•The mechanism of C2C12 cell proliferation was analysed by qRT-PCR and Western 
blot. 
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